Levodopa/carbidopa intestinal gel (LCIG), a formulation of levodopa and carbidopa infused into the intestines, can lower the duration of off episodes in people with advanced Parkinson’s disease, and is likely to be especially helpful to those whose daily episodes are long-lasting, an analysis of registry study…
Gocovri (amantadine) can reduce the number and duration of off episodes — periods during which levodopa-based treatments cease to be effective and motor symptoms return — as well as ease dyskinesia in patients with Parkinson’s, according to a post-hoc analysis of Phase 3 trials. These findings were presented…
A new Phase 3 clinical trial will test PhotoPharmics‘ light-based, at-home therapy device — called Celeste — for Parkinson’s disease. The “Celeste Light for PD Trial” — a collaboration between PhotoPharmics and the Center for Health + Technology (CHeT) at the University of Rochester Medical Center — will be conducted at…
People living with Parkinson’s disease report disruptions in care and worsening symptoms due to complications related to COVID-19, according to an online survey conducted by The Michael J. Fox Foundation. The Foundation, in collaboration with leading Parkinson’s researchers, conducted the survey through the online Fox Insight study,…
Problems with vision are more common in older people with Parkinson’s disease than in others of a similar age, and are linked with poorer health outcomes, a study based on U.S. Medicare records found. Fewer than 60% of the more than 285,000 Parkinson’s patients whose data were analyzed, however, had…
SpeechVive recently raised more than $1.5 million to support efforts to increase accessibility for the wearable medical device that improves the speech clarity of Parkinson’s disease patients. Capital from the syndicated funding round was provided by Elevate Ventures, Foundry Investment Fund, Southwest Angel Network, Racine Medical Angels,…
Parkinson’s disease may affect more than 1.6 million people in the United States by 2037, at an estimated annual economic burden of $79 billion, according to a recent study. The study, “Current and projected future economic burden of Parkinson’s disease in the U.S.,” was published in…
A multi-faceted intervention that included staff education, electronic alerts, and requiring new reports, improved the timeliness with which Parkinson’s disease patients were given medication in a hospital setting, a new study reports. This suggests that similar interventions might aid in the timeliness of Parkinson’s treatments in other hospitals. The study, “…
Pathogenic bacteria such as Salmonella typhimurium were seen for a first time to form biofilms, or dense clusters of bacteria that can adhere to surfaces and withstand harsh conditions, in the intestines of mice in a study. Salmonella was previously thought to only form biofilms in the environment. These biofilms…
A new technique shows that alpha-synuclein, the protein at the heart of Parkinson’s disease, affects cell membranes differently, based on their composition. This discovery sheds light on how alpha-synuclein clumps known as amyloids might disrupt cellular membranes, potentially helping to design therapies that might slow or stop…
Get regular updates to your inbox.